What should I do if I become resistant to vepotuzumab (POLIVY)?

Resistance may be due to adaptive changes in cancer cells to velpotuzumab (POLIVY). In this case, doctors may re-evaluate treatment options and consider a combination of other targeted drugs or chemotherapy drugs. If resistance emerges, participation in ongoing clinical trials may be an option. Clinical trials provide the opportunity to try new drugs or new treatment strategies, potentially leading to better treatment outcomes.

Vepotolizumab is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecule MMAE is an antimitotic agent. The monoclonal antibody binds to CD79b, which is a B cell-specific surface protein. When binding to CD79b, MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis. In patients with relapsed or refractory diffuse large B-cell lymphoma, lower acMMAE exposure (AUC) is associated with lower efficacy. However, everyone has different constitutions and different drug resistance responses. Please inform your doctor in time if you feel unwell.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.